Status:

COMPLETED

A Phase 2 Study of E6005 in Patients With Atopic Dermatitis

Lead Sponsor:

Organon and Co

Conditions:

Atopic Dermatitis

Eligibility:

All Genders

20-64 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the efficacy and safety profiles of E6005 ointment in patients with atopic dermatitis compared to vehicle. The pharmacokinetic profile after topical applicatio...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Adults of both genders aged 20 to 64 years at the time when the written informed consent is obtained.
  • Outpatients diagnosed with atopic dermatitis.
  • Exclusion Criteria
  • Patients with a present illness of Kaposi's varicelliform eruption, scabies, molluscum contagiosum, impetigo contagious, psoriasis, connective tissue disorder, collagen disorder or Netherton's syndrome, etc., which could have an effect on the pathological evaluation of the atopic dermatitis.
  • Patients with active infection that requires oral or intravenous administration of antibiotics, antifungal or antivirus agent/s at baseline.
  • Patients with advanced disease or abnormal laboratory tests that would possibly affect the safety of the subject or the implementation of this study.

Exclusion

    Key Trial Info

    Start Date :

    December 1 2011

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2013

    Estimated Enrollment :

    78 Patients enrolled

    Trial Details

    Trial ID

    NCT01461941

    Start Date

    December 1 2011

    End Date

    January 1 2013

    Last Update

    June 3 2025

    Active Locations (10)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (10 locations)

    1

    Nagoya, Aichi-ken, Japan

    2

    Urayasu-shi, Chiba, Japan

    3

    Fukuoka, Fukuoka, Japan

    4

    Asahikawa-shi, Hokkaido, Japan